Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system

Background: COVID-19 patients with underlying medical conditions are vulnerable to drug-drug interactions (DDI) due to the use of multiple medications. We conducted a discovery-driven data analysis to identify potential DDIs and associated adverse events (AEs) in COVID-19 patients from the FDA Adver...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Eugene, Nelson, Scott D., Su, Yu, Malin, Bradley, Li, Lang, Chen, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353301/
https://www.ncbi.nlm.nih.gov/pubmed/35935872
http://dx.doi.org/10.3389/fphar.2022.938552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353301/
https://www.ncbi.nlm.nih.gov/pubmed/35935872
http://dx.doi.org/10.3389/fphar.2022.938552

Ejemplares similares